On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Around 59 companies are set to announce their third quarter results on Thursday, including key players like Ultratech Cement, ...

Dr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

“This year, the industry is set to witness the launch of biosimilars for aflibercept, ustekinumab, and denosumab, and we are eager to track the market movements that they will generate,” said Thomas ...